CA224098: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma

Principal investigator: Micaela Hernberg
HUS Helsinki University Hospital, Comprehensive Cancer Center